Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405448 | 0.82 | MAPT (0.60) | MAPTL3MBTL1KMT2AMEN1HCAR3 | |
| SCHEMBL22191673 | 0.82 | MAPT (0.60) | MAPTL3MBTL1KMT2AMEN1HCAR3 | |
| SCHEMBL31481963 | 0.80 | MAPT (0.57) | MAPTL3MBTL1KMT2AMEN1HCAR3 | |
| SCHEMBL3512219 | 0.80 | MAPT (0.57) | MAPTL3MBTL1KMT2AMEN1HCAR3 | |
| SCHEMBL9386617 | 0.79 | TDP1 (0.43) | MAPTL3MBTL1KMT2AMEN1HCAR3 | |
| SCHEMBL7129606 | 0.78 | MAPT (0.56) | MAPTL3MBTL1KMT2AMEN1HCAR3 | |
| SCHEMBL17845498 | 0.78 | ATM (0.51) | MAPTTDP1ATMALDH1A1MAPK1 | |
| SCHEMBL15322458 | 0.78 | TDP1 (0.51) | MAPTL3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL30532042 | 0.78 | ATM (0.51) | MAPTTDP1ATMALDH1A1MAPK1 | |
| SCHEMBL1344661 | 0.78 | HCAR3 (0.58) | MAPTL3MBTL1KMT2AMEN1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-1482931-B1 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA INC (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2324830-A1 | Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage | TransTech Pharma Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| CN-101613321-A | The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction | TRANSTECH PHARMA INC | 2009-12-30 | — | — | CN | disclosed |
| CN-101597262-A | The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction | TRANSTECH PHARMA INC (US) | 2009-12-09 | — | — | CN | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-5185025-A | SUBSTITUTED PYRAZOLES AND THEIR USE AS HERBICIDES | MONSANTO COMPANY (US) | 1993-02-09 | — | — | US | disclosed |
| US-5045106-A | 3-phenoxypyrazole | MONSANTO COMPANY (US) | 1991-09-03 | — | — | US | disclosed |
| US-4964895-A | Substituted 4-(4-nitrophenoxy) pyrazoles and their use as herbicides | MONSANTO COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0371947-A1 | Substituted pyrazoles and their use as herbicides | Monsanto Company (US) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 526/4885L3MBTL1 4864/4885KMT2A 4844/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 406/4885L3MBTL1 4864/4885KMT2A 4802/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 430/4885L3MBTL1 4861/4885KMT2A 4827/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | MAPT 430/4885L3MBTL1 4861/4885KMT2A 4827/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 430/4885L3MBTL1 4861/4885KMT2A 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.